XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net loss $ (375,014) $ (405,273)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 64,267 53,345
Loss on disposal of property, plant and equipment 928 930
Unrealized (gain) loss on equity investments 1,937 (1,183)
Deferred tax benefit (248,716) (6,161)
Stock-based compensation 197,180 111,075
Post-combination expense for acceleration of unvested equity 80,960 0
Realized gain on preferred stock investment (30,500) 0
Loss on settlement of convertible notes 0 50,819
Amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities 4,948 340
Amortization of premium on short-term investments 3,265 1,040
Amortization of acquired intangible assets 70,954 70,199
Intangible asset impairment charge 20,210 209,666
Asset acquisition IPR&D expense 85,337 0
Remeasurement of contingent consideration 10,986 0
Non-cash lease expense 18,347 11,041
Changes in assets and liabilities:    
Accounts receivable, net (14,038) (73,642)
Inventory, net (1,091) (18,472)
Operating lease liabilities (11,834) (6,135)
Accounts payable and accrued liabilities 64,344 (7,608)
Other assets and liabilities (20,134) 35,097
Net cash provided by (used in) operating activities (77,664) 25,078
Cash flows from investing activities:    
Purchases of marketable securities (1,021,557) (890,012)
Maturities and sales of marketable securities 424,830 559,907
Purchases of property, plant and equipment (76,374) (48,371)
Business combination, net of cash acquired (415,549) (6,658)
Asset acquisition (58,073) 0
Investments in privately held companies (13,555) (10,610)
Other investing activities (244) 345
Net cash used in investing activities (1,160,522) (395,399)
Cash flows from financing activities:    
Proceeds from issuance of convertible notes, net 0 1,125,547
Proceeds from exercise of common stock options 13,372 15,408
Proceeds in connection with the Company’s employee stock purchase plan 12,038 9,799
Payments on settlement of convertible notes 0 (150,054)
Other financing activities (4,742) (938)
Net cash provided by financing activities 20,668 999,762
Net increase (decrease) in cash, cash equivalents and restricted cash (1,217,518) 629,441
Cash, cash equivalents and restricted cash, beginning of period 1,491,594 177,528
Cash, cash equivalents and restricted cash, end of period 274,076 806,969
Supplemental disclosure of non-cash investing and financing activities:    
Property, plant and equipment acquired but not paid 21,110 7,209
Unrealized gain (loss) on available-for-sale investments, before tax (563) 1,159
Issuance of 162,606 and 136,559 shares of common stock to fund the Company’s 401(k) matching contribution for 2020 and 2019, respectively 22,934 12,007
Issuance of 9,510,436 and 382,947 shares of common stock for business combinations and asset acquisition for 2021 and 2020, respectively 1,270,918 28,847
Business combination contingent consideration liability 350,348 0
Supplemental disclosure of cash flow information:    
Interest paid $ 10,685 $ 9,239